Search - tctmd.com

Displaying 201 - 211 of 211

Sort: Relevancy | Date

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

March 09, 2013

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

Advertisement

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content